论文部分内容阅读
目的探讨雷替曲塞联合多西他塞对进展期胃癌患者血管内皮生长因子(VEGF)的影响。方法选取2013年1月至2015年12月间邢台市人民医院收治的28例进展期胃癌患者,均行雷替曲塞联合多西他塞化疗4~6个周期,检测血管内皮生长因子水平。结果化疗前1 d和化疗后1 d、1周、1个月及4~6个周期后,患者VEGF水平分别为(298.5±23.4)ng/L、(473.5±68.5)ng/L、(268.3±47.9)ng/L、(290.7±32.4)ng/L和(232.4±21.6)ng/L,化疗后1 d、1周和4~6个化疗周期后的VEGF水平与化疗前比较,差异均有统计学意义(均P<0.05);化疗4~6个周期后,总有效率为46.4%,VEGF水平为(202.4±23.4)ng/L,低于化疗前的(298.5±23.4)ng/L,差异有统计学意义(P<0.05)。结论雷替曲塞联合多西他塞药物化疗后,进展期胃癌患者VEGF水平明显降低。
Objective To investigate the effect of ralterexed and docetaxel on vascular endothelial growth factor (VEGF) in patients with advanced gastric cancer. Methods Twenty-eight patients with advanced gastric cancer admitted to Xingtai People’s Hospital from January 2013 to December 2015 were enrolled in the study. The patients were treated with raltitrexed and docetaxel for 4 to 6 cycles, and the levels of vascular endothelial growth factor (VEGF) were detected. Results The levels of VEGF were (298.5 ± 23.4) ng / L, (473.5 ± 68.5) ng / L, and (268.3 ± 4.45) ng / L respectively at 1 d before chemotherapy and at 1 d, 1 week, 1 month and 4 to 6 cycles after chemotherapy. ± 47.9 ng / L, (290.7 ± 32.4) ng / L and (232.4 ± 21.6) ng / L, respectively. The levels of VEGF after 1, 1 and 4 to 6 chemotherapy cycles after chemotherapy were significantly lower than those before chemotherapy (P <0.05). The total effective rate was 46.4% and the level of VEGF was (202.4 ± 23.4) ng / L after 4 to 6 cycles of chemotherapy, which was lower than that before chemotherapy (298.5 ± 23.4) ng / L, the difference was statistically significant (P <0.05). Conclusions Raltitrexed combined with docetaxel chemotherapy significantly reduces the level of VEGF in patients with advanced gastric cancer.